P2y13 Receptor Regulates Hdl Metabolism And Atherosclerosis In Vivo

High-density lipoprotein (HDL) is known to protect against atherosclerosis by promoting the reverse cholesterol transport. A new pathway for the regulation of HDL-cholesterol (HDL-c) removal involving F1-ATPase and P2Y13 receptor (P2Y13) was described in vitro, and recently in mice. However, the physiological role of F1-ATPase/P2Y13 pathway in the modulation of vascular pathology i. e. in the development of atherosclerotic plaques is still unknown. We designed a specific novel agonist (CT1007900) of the P2Y13 that caused stimulation of bile acid secretion associated with an increased uptake of HDL-c in the liver after single dosing in mice. Repeated dose administration in mice, for 2 weeks, stimulated the apoA-I synthesis and formation of small HDL particles. Plasma samples from the agonist-treated mice had high efflux capacity for mobilization of cholesterol in vitro compared to placebo group. In apoE(-/-) mice this agonist induced a decrease of atherosclerotic plaques in aortas and carotids. The specificity of P2Y13 pathway in those mice was assessed using adenovirus encoding P2Y13-shRNA. These results demonstrate that P2Y13 plays a pivotal role in the HDL metabolism and could also be a useful therapeutic agent to decrease atherosclerosis. In this study, the up-regulation of HDL-c metabolism via activation of the P2Y13 using agonists could promote reverse cholesterol transport and promote inhibition of atherosclerosis progression in mice.